Lurbinectedin 单药治疗复发/难治性尤文肉瘤儿童和青年参与者的研究
一项 1/2 期、开放标签研究,旨在评估 Lurbinectedin 单药治疗儿童参与者的安全性、耐受性、药代动力学 (PK)、推荐的 2 期剂量 (RP2D) 和疗效,随后扩展以评估疗效和疗效患有复发/难治性尤文肉瘤的儿科和青年参与者的安全性。
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Clinical Trial Disclosure & Transparency
- 电话号码:215-832-3750
- 邮箱:ClinicalTrialDisclosure@JazzPharma.com
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 1X8
- 招聘中
- The Hospital for Sick Children
-
-
-
-
California
-
Los Angeles、California、美国、90027
- 招聘中
- Children's Hospital of Los Angeles
-
Palo Alto、California、美国、94304
- 招聘中
- Lucile Packard Children's Hospital
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- 招聘中
- Children's National Hospital
-
-
Florida
-
St. Petersburg、Florida、美国、33701
- 招聘中
- Johns Hopkins All Children's Hospital
-
-
Georgia
-
Atlanta、Georgia、美国、30329
- 招聘中
- Children's Healthcare of Atlanta at Arthur M. Blank Hospital
-
-
Maryland
-
Baltimore、Maryland、美国、21238
- 招聘中
- Johns Hopkins University
-
-
Michigan
-
Grand Rapids、Michigan、美国、49503
- 招聘中
- Corewell Health
-
-
New York
-
New York、New York、美国、10065
- 招聘中
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- 招聘中
- Duke University School of Medicine
-
-
Ohio
-
Cincinnati、Ohio、美国、45229
- 招聘中
- Cincinnati Children's Hospital Medical Center
-
Columbus、Ohio、美国、43205
- 招聘中
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Memphis、Tennessee、美国、38105
- 招聘中
- St. Jude Children's Research Hospital
-
-
Texas
-
Dallas、Texas、美国、75235
- 招聘中
- Children's Health Dallas
-
Houston、Texas、美国、77030
- 招聘中
- The University of Texas MD Anderson Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
Age
-
Participant must meet the following age requirements at the time the informed consent form (ICF) (and assent form, if applicable) is signed:
- Phase 1 Part 1: participants must be ≥ 2 to < 18 years of age.
- Phase 1 Part 2: participants must be ≥ 2 to ≤ 30 years of age.
- Phase 2: participants must be ≥ 2 to ≤ 30 years of age.
Type of Participant and Disease Characteristics
-
Participant has a confirmed solid tumor
-
The participant has a Lansky/Karnofsky performance status score of ≥ 50%.
-
The participant has adequate liver function, evidenced by the following laboratory values:
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN).
- Total bilirubin ≤ 1.5 × institutional ULN (with the exception of participants with Gilbert's syndrome who must have bilirubin < 3 × institutional ULN).
-
The participant has adequate bone marrow function, evidenced by the following:
- Absolute neutrophil count (ANC) ≥ 1.0 × 10^9/L (independent of growth factor support within 1 week of screening laboratories).
-
Platelets ≥ 100 × 10^9/L (without platelet transfusion within previous 7 days of screening laboratories).
- Hemoglobin ≥ 8 g/dL (note: may have been transfused).
-
The participant has an adequate renal function:
- Calculated creatinine clearance (use Cockcroft-Gault formula for participants ≥ 18 years; Schwartz equation for participants < 18 years) ≥ 60 mL/min.
-
The participant has an adequate cardiac function:
- Left ventricular ejection fraction or shortening fraction per institutional norm ≥ institutional lower level of normal.
-
The participant has creatine phosphokinase ≤ 2.5 × institutional ULN.
Weight
- The participant has body weight ≥ 15 kg.
Sex and Contraceptive/Barrier Requirements
Male participants:
Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 4 months after the last dose of study intervention:
- Refrain from donating sperm.
PLUS, either:
- Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.
OR
-
Must agree to use contraception/barrier as detailed below:
- Agree to use a male condom with female partner and use of an additional highly effective contraceptive method with a failure rate of < 1% per year when having sexual intercourse with a Woman of childbearing potential (WOCBP) who is not currently pregnant.
- Note: male participants who are azoospermic (vasectomized or due to a medical cause) are still required to follow the protocol-specified contraception/barrier criteria.
Female participants:
A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
-
Is a Woman of nonchildbearing potential (WONCBP). OR
-
Is a WOCBP and using an acceptable contraceptive method during the study intervention period (at least 7 months after the last dose of study intervention). The investigator should evaluate the potential for contraceptive method failure (eg, noncompliance, recently initiated) in relationship to the first dose of study intervention.
-
A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 7 days before the first dose of study intervention.
- If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
-
Additional requirements for pregnancy testing during and after study intervention.
-
The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
Informed Consent
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Key Exclusion Criteria:
Medical Conditions
- corrected QT interval (QTc) prolongation defined as a QTc ≥ 460 ms using the Bazett formula in age < 18 years and QTc ≥ 470 ms using the Bazett formula in age ≥ 18 years.
- Known symptomatic Central nervous system (CNS) metastases requiring steroids. Participants with previously diagnosed CNS metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to enrollment, have discontinued high dose steroid treatment for these metastases for at least 2 weeks, and are neurologically stable (physiologic doses of steroids and short courses of steroids for other indications are acceptable).
- Persisting toxicity related to prior therapy; however, alopecia, sensory neuropathy, hypothyroidism, and rash Grade ≤ 2 are acceptable, and other Grade ≤ 2 adverse events (AEs) not constituting a safety risk based on the investigator's judgement are acceptable.
- An uncontrolled intercurrent illness including but not limited to ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy, symptomatic heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Any other major illness that, in the investigator's judgment, could substantially increase the risk associated with participation in this study.
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high-risk for treatment complications.
Prior/Concomitant Therapy
- Received prior treatment with lurbinectedin or trabectedin.
- Received prior treatment with any investigational product within 4 weeks of first infusion of study intervention. Observational studies are permitted.
- Received live or live attenuated vaccines within 4 weeks of the first dose of study treatment or plans to receive live vaccines during study participation. Administration of inactive vaccines or messenger ribonucleic acid (mRNA) vaccines (for example, inactivated influenza vaccines or COVID-19 vaccines) are allowed.
- Had major surgery ≤ 4 weeks or radiation therapy ≤ 2 weeks prior to enrollment unless fully recovered. Prior palliative radiotherapy is permitted, provided it was completed at least 2 weeks prior to participant enrollment.
- Received prior allogeneic bone marrow transplantation or solid organ transplant.
- Received chemotherapy ≤ 3 weeks prior to start of study intervention.
Diagnostic Assessments
- Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or Polymerase chain reaction (PCR) test for HCV RNA if HCV antibody test is positive).
- Human immunodeficiency infection at screening (positive anti-HIV antibody).
Other Exclusions
- Has a known or suspected hypersensitivity to any of the components of the study intervention.
- The participant or parent(s)/guardian(s) is/are unable to comply with the study visit schedule and other protocol requirements, in the opinion of the investigator
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Phase 1 Part 1: Dose Selection
Pediatric participants ≥ 2 to < 18 years of age with previously treated solid tumors of any histology at 5 dose levels to determine the RP2D, followed by a safety expansion cohort. Participants aged ≥ 6 to < 18 years will be enrolled at the starting dose of 3.2 mg/m^2 lurbinectedin. If, after review, the starting dose of 3.2 mg/m^2 lurbinectedin Q3W is deemed safe in participants aged ≥ 6 to < 18 years, participants aged ≥ 2 to < 6 years may enroll and start at the dose as determined by the DMC. After this, the study opens to all participants (aged ≥ 2 to < 18 years) for all dose levels. Upon completion of the cohort at all dose levels, participants may be eligible to enroll in a safety expansion cohort. |
Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
其他名称:
|
|
实验性的:Phase 1 Part 2: RP2D
Participants aged ≥ 2 to ≤ 30 years with recurrent/refractory Ewing sarcoma at the RP2D to assess safety and efficacy signals. |
Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
其他名称:
|
|
实验性的:Phase 2
If a signal of efficacy is observed in Phase 1 Part 2, additional participants aged ≥ 2 to ≤ 30 years with recurrent/refractory Ewing sarcoma will be enrolled. Phase 2 will further assess the safety and efficacy of lurbinectedin monotherapy. |
Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
第一阶段:出现剂量限制性毒性(DLT)的参与者人数
大体时间:从首次给药至第1周期(21天)结束。
|
从首次给药至第1周期(21天)结束。
|
|
第一阶段:经历严重不良事件(SAEs)和治疗出现不良事件(TEAEs)的参与者数量
大体时间:基线后(第1天)至约31个月。
|
基线后(第1天)至约31个月。
|
|
第一阶段:剂量调整的参与者人数
大体时间:基线后(第 1 天)至大约 31 个月。
|
基线后(第 1 天)至大约 31 个月。
|
|
第一阶段:因治疗期间出现的不良事件(TEAEs)而中止研究干预的受试者人数
大体时间:基线后(第 1 天)至约 31 个月。
|
基线后(第 1 天)至约 31 个月。
|
|
第2阶段:基于研究者评估(IA)的客观缓解率(ORR)
大体时间:给药后第-28天至总共13个月。
|
给药后第-28天至总共13个月。
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
第 1 阶段:基于研究者评估 (IA) 的客观缓解率 (ORR)
大体时间:第 -28 天到给药后总共 31 个月。
|
第 -28 天到给药后总共 31 个月。
|
|
第 1 阶段:基于研究者评估 (IA) 的无进展生存期 (PFS)
大体时间:第 -28 天到给药后总共 31 个月。
|
第 -28 天到给药后总共 31 个月。
|
|
第 1 阶段:确认完全缓解 (CR) 或部分缓解 (PR) 的参与者的缓解持续时间 (DOR)
大体时间:第 -28 天到给药后总共 31 个月。
|
第 -28 天到给药后总共 31 个月。
|
|
第一阶段:疾病控制率 (DCR)
大体时间:第 -28 天到给药后总共 31 个月。
|
第 -28 天到给药后总共 31 个月。
|
|
第 1 阶段:至少 12 周内疾病稳定 (SD) 的临床受益率 (CBR)
大体时间:第 -28 天到给药后总共 31 个月。
|
第 -28 天到给药后总共 31 个月。
|
|
第 1 阶段:总生存期 (OS)
大体时间:给药后长达 31 个月的基线后(第 1 天)。
|
给药后长达 31 个月的基线后(第 1 天)。
|
|
第 2 阶段:Lurbinectedin 的血浆浓度
大体时间:第 1 天:给药前至给药后约 168 小时;第 16、31、46 天:给药前至给药后约 5 分钟。
|
第 1 天:给药前至给药后约 168 小时;第 16、31、46 天:给药前至给药后约 5 分钟。
|
|
第一阶段:卢比奈克替丁的血浆浓度
大体时间:第1天:给药前至给药后约168小时;第16、31、46天:给药前至给药后约5分钟。
|
第1天:给药前至给药后约168小时;第16、31、46天:给药前至给药后约5分钟。
|
|
第一阶段:呼吸频率相对于基线的变化
大体时间:基线后(第1天)至大约31个月。
|
基线后(第1天)至大约31个月。
|
|
第一阶段:脉搏率相对于基线的变化
大体时间:基线后(第 1 天)至约 31 个月。
|
基线后(第 1 天)至约 31 个月。
|
|
第一阶段:血压相对基线的变化
大体时间:基线后(第 1 天)至约 31 个月。
|
基线后(第 1 天)至约 31 个月。
|
|
第一阶段:体重相对于基线的变化
大体时间:基线后(第1天)至约31个月。
|
基线后(第1天)至约31个月。
|
|
第一阶段:血小板计数相对于基线的变化
大体时间:基线后(第1天)至约31个月。
|
基线后(第1天)至约31个月。
|
|
第一阶段:红细胞计数相对于基线的变化
大体时间:基线后(第1天)至约31个月。
|
基线后(第1天)至约31个月。
|
|
第一阶段:血红蛋白较基线的变化
大体时间:基线后(第 1 天)至约 31 个月。
|
基线后(第 1 天)至约 31 个月。
|
|
第一阶段:与基线相比的差异白细胞计数变化
大体时间:基线后(第1天)至约31个月。
|
基线后(第1天)至约31个月。
|
|
第一阶段:AST/ALT水平相对于基线的变化
大体时间:基线后(第1天)至约31个月。
|
基线后(第1天)至约31个月。
|
|
第一阶段:肌酐水平相对于基线的变化
大体时间:基线后(第1天)至约31个月。
|
基线后(第1天)至约31个月。
|
|
第一阶段:CPK水平较基线的变化
大体时间:基线后(第1天)至约31个月。
|
基线后(第1天)至约31个月。
|
|
第2阶段:经历严重不良事件(SAEs)和治疗期出现的不良事件(TEAEs)的参与者人数
大体时间:基线后(第1天)至大约13个月。
|
基线后(第1天)至大约13个月。
|
|
第二阶段:剂量调整的参与者人数
大体时间:基线后(第1天)至约13个月。
|
基线后(第1天)至约13个月。
|
|
第二阶段:因治疗期间出现的不良事件(TEAE)而停止研究干预的参与者人数
大体时间:基线后(第1天)至大约13个月。
|
基线后(第1天)至大约13个月。
|
|
第二阶段:基于独立评估(IA)的无进展生存期(PFS)
大体时间:第-28天至给药后总计13个月。
|
第-28天至给药后总计13个月。
|
|
第二阶段:经确认完全缓解(CR)或部分缓解(PR)参与者的缓解持续时间(DOR)
大体时间:从给药前28天至给药后共计13个月。
|
从给药前28天至给药后共计13个月。
|
|
第二期:疾病控制率(DCR)
大体时间:给药前第28天至给药后总计13个月内。
|
给药前第28天至给药后总计13个月内。
|
|
第二阶段:临床获益率(CBR),包含稳定期(SD)至少12周
大体时间:第-28天至给药后总计13个月。
|
第-28天至给药后总计13个月。
|
|
第二阶段:总生存期(OS)
大体时间:基线后(第1天)至给药后13个月。
|
基线后(第1天)至给药后13个月。
|
|
第二阶段:呼吸频率相对基线的变化
大体时间:基线后(第1天)至大约13个月。
|
基线后(第1天)至大约13个月。
|
|
第二阶段:脉率相对于基线的变化
大体时间:基线后(第1天)至约13个月。
|
基线后(第1天)至约13个月。
|
|
第二阶段:血压相对基线的变化
大体时间:基线后(第1天)至大约13个月。
|
基线后(第1天)至大约13个月。
|
|
第二阶段:体重相对于基线的变化
大体时间:基线后(第1天)至约13个月。
|
基线后(第1天)至约13个月。
|
|
第二阶段:血小板计数相对于基线的变化
大体时间:基线后(第1天)至大约13个月。
|
基线后(第1天)至大约13个月。
|
|
第二阶段:红细胞计数较基线的变化
大体时间:基线后(第1天)至约13个月。
|
基线后(第1天)至约13个月。
|
|
第二阶段:血红蛋白相对于基线的变化
大体时间:基线后(第1天)至约13个月。
|
基线后(第1天)至约13个月。
|
|
第二阶段:与基线相比的差异白细胞计数变化
大体时间:基线后(第1天)至约13个月。
|
基线后(第1天)至约13个月。
|
|
第二阶段:AST/ALT水平相对基线的变化
大体时间:基线后(第1天)至大约13个月。
|
基线后(第1天)至大约13个月。
|
|
第二阶段:肌酐水平相对基线的变化
大体时间:基线后(第1天)至大约13个月。
|
基线后(第1天)至大约13个月。
|
|
第二阶段:CPK水平相对于基线的变化
大体时间:基线后(第1天)至约13个月。
|
基线后(第1天)至约13个月。
|
合作者和调查者
调查人员
- 研究主任:Jazz Study Director、Jazz Pharmaceuticals
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.